Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

study is expected to complete the minimum 12 patients by the end of the third quarter of fiscal 2010.
  • Enrollment in the ongoing Phase II clinical trial of Topical Interferon Alpha-2b in patients with anogenital warts ("AGW") in Sweden and Germany is progressing on track. The Company expects the last patient to be enrolled on or around the end of the first quarter of fiscal 2010. The study has now enrolled over 93% of the required 120 patients.
  • Financing

    • Completed a private placement financing on October 2, 2008 for gross proceeds of $11,424,000.
    • Completed a private placement financing on September 8, 2009 for gross proceeds of $13,581,250.
    • Prof. Majewski, stepped down from the Board of Directors to assume the advisory role of European medical director, effective August 11, 2009.
    • Prof. Kazimierz Roszkowski-Sliz was appointed to the Board of Directors on August 17, 2009.

    FINANCIAL REVIEW

    For fiscal 2009, the Company recorded a net loss of $14,102,000, which represents an increase of $7,138,000 when compared to fiscal 2008. The net loss per common share for fiscal 2009 was $0.27 and represents an increase of $0.11 in loss per common share when compared to fiscal 2008. Product revenue contributed to the increase in revenue in fiscal 2009 and overall expenses were higher when compared to fiscal 2008 which mainly reflect higher research and development expenditures, stock-based compensation expense associated with stock options granted in the second quarter, lower interest income and a foreign exchange loss.

    Total revenues in fiscal 2009 were $3,841,000 and represent an increase of $250,000 or 7.0% when compared to total revenues in fiscal 2008 of $3,591,000. Product revenue contributed to the increase in revenue in fiscal 2009 when compared to fiscal 2008 and was offset slightly by a decrease in license fees and royalties.


    '/>"/>
    SOURCE Helix BioPharma Corp.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
    2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
    3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
    5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
    6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
    7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
    8. PDL BioPharma Completes October 1 Special Dividend Payment
    9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
    10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
    11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
    (Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
    (Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... Improved Long-term [Five-years],Overall Survival for these Seriously ... -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, provided significant,improvements ... and,time to disease progression (TTP) - a ... with metastatic (advanced) colorectal cancer.,Importantly, the FOLFOX4 ...
    ... Presented at Society of Nuclear,Medicine Annual Meeting ... Inc. , a biopharmaceutical company focused on,developing ... serious,diseases, today announced that its anti-carcinoembryonic antigen,(CEA) ... found to be safe and active when ...
    Cached Medicine Technology:Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
    (Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
    (Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
    (Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
    (Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
    (Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
    Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
    ... ... for the treatment of acute injuries and chronic conditions affecting soft tissues, such as ... ... Therapy, a leading provider of physical medicine and rehabilitation services in the metropolitan New ...
    ... Arizona criminal attorney ... case of State v. Norton. The Downtown Justice Court suppressed Norton,s breath alcohol readings of ... Phoenix, ... was able to get the breath alcohol readings suppressed in the case of State V. ...
    ... Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month: , ... , , ... ... "BHR Pharma ...
    ... March 23 Healthcare organizations looking to reduce costs and improve patient care by extending their information management to the mobile world can now do so without undergoing ... ... ... ...
    ... secure and trusted environment using MobiSecure® SMS, a new product introduced today by Diversinet Corp. (OTC Bulletin Board: DVNTF; TSX Venture: DIV). , ... , ... ... ...
    ... be harder to lie about your age or your poker ... has revealed that our eye position betrays the numbers we ... asked to state a series of random numbers. By measuring ... predict with reliable confidence the next chosen number - before ...
    Cached Medicine News:Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 2Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 3Health News:Arizona Criminal Attorney Gets Breath Alcohol Readings Suppressed 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 2Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 4Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 5Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 6Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 7Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 2Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 3Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 4Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 5Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 6Health News:Our eye position betrays the numbers we have in mind, new study 2
    This legless table has adjustable height and round post. Pad sold separately....
    This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
    This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
    ... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
    Medicine Products: